...
首页> 外文期刊>Pharmacological research: The official journal of The Italian Pharmacological Society >A bradykinin antagonist abolishes beneficial effect of captopril on duration of survival after acute coronary artery ligation in hypertensive rats.
【24h】

A bradykinin antagonist abolishes beneficial effect of captopril on duration of survival after acute coronary artery ligation in hypertensive rats.

机译:缓激肽拮抗剂消除了卡托普利对高血压大鼠急性冠状动脉结扎后存活时间的有益作用。

获取原文
获取原文并翻译 | 示例
           

摘要

It has been recently suggested that bradykinin (BK) may act as a cardioprotective agent. In the present investigation, we evaluated the effects of captopril, an angiotensin-converting enzyme inhibitor (ACEI), and kinin B2 receptor antagonist, D-Arg-[Hyp3-D-Phe7]-BK, on the duration of survival after acute coronary artery ligation for 15 min in spontaneously hypertensive rats (SHR). The captopril treatment (16 and 32 ug/kg, i.v.) resulted in a significant (p < 0.05) increase in survival time of SHR as compared with saline-treated control SHR. Kinin B2 receptors antagonist (4 ug/kg, i.v.) pretreatment abolished (p > 0.05) the beneficial effect of captopril on survival time as compared to saline-treated control SHR. Both the ligation of coronary artery and captopril treatment resulted in a significant (p < 0.001) fall in systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) of SHR as compared to the saline-treated control SHR. In addition, captopril administration caused a significant (p < 0.05) fall in the SBP, DBP and HR of SHR before ligation of the coronary artery (preligation). However, there was no significance (p > 0.05) in SBP, DBP and HR between saline- and kinin B2 receptor antagonist plus captopril-treated SHR during preligation. These finding might indicate that captopril possesses a cardioprotective property as demonstrated by increased in survival time of SHR. This beneficial effect of captopril is mediated via the kinin B2 receptor pathway because kinin B2 receptor antagonist pretreatment blocked the captopril-induced increase in survival time of SHR.
机译:最近已经提出,缓激肽(BK)可以充当心脏保护剂。在本研究中,我们评估了血管紧张素转换酶抑制剂(ACEI)卡托普利和激肽B2受体拮抗剂D-Arg- [Hyp3-D-Phe7] -BK对急性冠状动脉术后生存时间的影响自发性高血压大鼠(SHR)的动脉结扎15分钟。与盐水处理的对照SHR相比,卡托普利治疗(16和32 ug / kg,静脉内)导致SHR的生存时间显着增加(p <0.05)。与盐水处理的对照SHR相比,激肽B2受体拮抗剂(4 ug / kg,静脉)取消了卡托普利对生存时间的有益作用(p> 0.05)。与盐水治疗的对照SHR相比,结扎冠状动脉和卡托普利治疗均导致SHR的收缩压(SBP),舒张压(DBP)和心率(HR)显着下降(p <0.001) 。另外,在结扎冠状动脉之前(结扎),卡托普利的使用导致SHR的SBP,DBP和HR显着下降(p <0.05)。但是,在预结扎过程中,盐水和激肽B2受体拮抗剂加卡托普利治疗的SHR之间的SBP,DBP和HR没有显着差异(p> 0.05)。这些发现可能表明卡托普利具有心脏保护作用,如SHR生存时间增加所证明。卡托普利的这种有益作用是通过激肽B2受体途径介导的,因为激肽B2受体拮抗剂的预处理阻止了卡托普利诱导的SHR生存时间的增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号